← Back to Search

Financial Incentives + Communication Training for HPV Vaccine Uptake

N/A
Recruiting
Led By Justin G Trogdon, PhD
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 13 months to 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will explore how financial incentives + communication training can increase HPV vaccine uptake in clinics.

Who is the study for?
This trial is for pediatric or family medicine clinics in North Carolina with less than a 72% HPV vaccine initiation rate and at least 50 patients aged 9-12. Clinics must have at least two providers offering the HPV vaccine and no recent financial incentives or communication training aimed at increasing vaccination rates.
What is being tested?
The study is testing if giving clinics financial rewards, along with communication training, increases the number of kids getting the HPV vaccine. Some clinics will just get training, while others will also receive money based on their performance plus monthly progress reports.
What are the potential side effects?
Since this trial involves non-medical interventions (financial incentives and communication training), there are no direct medical side effects to participants. However, it's important to monitor for any unintended consequences that these incentives might have on clinic practices.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 13 months to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from 13 months to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
HPV vaccination (≥1 dose), 9-12 year olds
HPV vaccination (≥2 doses), 9-12 year olds

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: HPV vaccine communication training.Experimental Treatment1 Intervention
Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination.
Group II: HPV vaccine communication training and clinic-level financial incentive programExperimental Treatment2 Interventions
Staff in clinics randomized to this arm will receive the Announcement Approach Training and a clinic-level financial incentive program with a monthly data feedback report to increase HPV vaccine uptake.

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
365 Previous Clinical Trials
92,687 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,956 Previous Clinical Trials
41,112,074 Total Patients Enrolled
Justin G Trogdon, PhDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill

Media Library

Communication training Clinical Trial Eligibility Overview. Trial Name: NCT05744960 — N/A
Human Papillomavirus Research Study Groups: HPV vaccine communication training and clinic-level financial incentive program, HPV vaccine communication training.
Human Papillomavirus Clinical Trial 2023: Communication training Highlights & Side Effects. Trial Name: NCT05744960 — N/A
Communication training 2023 Treatment Timeline for Medical Study. Trial Name: NCT05744960 — N/A
~8 spots leftby Jul 2025